The article details the groundbreaking capabilities of the JUNO-Checked biosensor, which quantifies sperm binding to a JUNO-functionalized surface by generating a metric, the JUNOScore. Since the ability of a sperm cell to bind to the egg’s JUNO protein is a crucial factor for fertilization, this innovative technology provides critical insights into sperm function, insights that traditional microscopic semen analysis cannot attain. By directly assessing this fundamental biological interaction, the research highlights the significant potential of the JUNO-Checked technology to enhance clinical diagnostics and optimize personalized assisted reproductive treatments, positioning it as a transformative tool in reproductive health.

The publication is the result of a productive collaboration with Reproductive Medicines Center (RMC) in Malmö and FlexMedical Solutions in the UK, which has been instrumental in developing the technology.

Spermosens is currently conducting a clinical study with the Reproductive Medicine Center (RMC) in Malmö to validate the JUNO-Checked biosensor’s potential in fertility diagnostics. Additionally, the company recently secured a strategic investment, strengthening its financial position to accelerate technical and clinical development, paving the way for partnerships and license agreements.

Tore Duvold, CEO of Spermosens, comments: "I am very pleased with the publication of our scientific results, which highlights the diagnostic relevance and clinical potential of our JUNO-Checked technology. This peer-reviewed study validates the quality of our research and its contribution to reproductive medicine, strengthening our commitment to advancing fertility diagnostics and enabling personalized treatment strategies."

For further details, please access the full article online at:
https://pubs.rsc.org/en/content/articlelanding/2025/sd/d5sd00009b

For further information, please contact:
Tore Duvold, CEO
E-mail: info@spermosens.com

Spermosens AB Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checked product aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market. The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com